02 November 2022
Volume 4 · Issue 11


In this column, Sharon Rees aims to refresh knowledge and interest in some of the commonly used drugs in a series of tweets. This month she is talking about #daptomycin

Day 1: #daptomycin was discovered in the late 1980s, when Streptomyces roseoporus bacteria was isolated from a Turkish soil sample. Adverse effects led to delays in clinical trials (muscle/neurotoxicity), until research into dosing regimens afforded safe and effective once-daily use. Licensed in 2003.

Day 2: #daptomycin is used in those over 1 year by iv infusion for complicated skin and soft tissue infections, endocarditis and bacteraemia from a broad range of gram +ve bacteria, eg S.aureus/MRSA/VRSA/VRE. Therapeutic range depends on infection and age, eg child 2-17yrs range 5-12 mg/kg; adult 4-6 mg/kg.

Day 3: #daptomycin kinetics; no oral absorption therefore iv infusion once/day for 7–14 days. Low Vd and unknown metabolism processes. Renal excretion with around 50% unchanged drug. T½ ~7–9 hrs, which is increased if renal impairment. Monitor renal function and if severe, decrease the dose or change dose interval to alternate days.

Day 4: #daptomycin is a bactericidal cyclic lipopeptide antibiotic, which has a fatty acid ‘tail’. Full mode of action is unclear, but known to insert the ‘tail’ into the bacterial cell membrane, complexing with Ca+. This causes changes in fluidity and membrane potential, leading to leakage and cell death.

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month